Jacob Vincent Micallef - 21 Sep 2021 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role
Chief Scientific Officer
Signature
/s/ Jacob Vincent Micallef
Issuer symbol
VNRX
Transactions as of
21 Sep 2021
Net transactions value
$0
Form type
4
Filing time
23 Sep 2021, 16:44:03 UTC
Previous filing
16 Jul 2021
Next filing
05 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNRX Option (Right to Buy) Disposed to Issuer $0 -66,533 -100% $0.000000* 0 16 Dec 2019 Common Stock 66,533 $5.00 Direct F1
transaction VNRX Option (Right to Buy) Award $0 +66,533 $0.000000 66,533 21 Sep 2021 Common Stock 66,533 $5.00 Direct F1
transaction VNRX Option (Right to Buy) Disposed to Issuer $0 -70,000 -100% $0.000000* 0 13 Apr 2020 Common Stock 70,000 $3.60 Direct F2
transaction VNRX Option (Right to Buy) Award $0 +70,000 $0.000000 70,000 21 Sep 2021 Common Stock 70,000 $3.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.
F2 The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.